打开APP

Covidien赢得与Applied Medical Resources专利战

  1. Applied Medical Resources
  2. Covidien
  3. 专利诉讼
  4. 医疗器械

来源:生物谷 2013-09-04 09:46

2013年9月3日讯 /生物谷BIOON/ --Covidien公司刚刚赢得了与Applied Medical Resources公司关于一项手术医疗器械的专利战。这项医疗器械是一种用于手术中的套管针。公司负责手术设备的Steve Blazejewski表示,法院支持Covidien公司的专利诉讼请求意味着承认了公司产品的与众不同。

2013年9月3日讯 /生物谷BIOON/ --Covidien公司刚刚赢得了与Applied Medical Resources公司关于一项手术医疗器械的专利战。这项医疗器械是一种用于手术中的套管针。公司负责手术设备的Steve Blazejewski表示,法院支持Covidien公司的专利诉讼请求意味着承认了公司产品的与众不同。而作为小型医疗器械公司的Applied Medical公司拥有2800名员工,而Covidien公司则在全球拥有38000名工作人员。(生物谷Bioon.com)

详细英文报道:

Covidien ($COV) won again in yet another patent challenge from a persistent rival, its latest dustup over a medical instrument known as a trocar.

The global medical device and supplies juggernaut said it prevailed against Applied Medical Resources in the U.S. Court of Appeals for the Federal Circuit on Aug. 27, more than two years after the southern California company filed its initial lawsuit. Covidien noted that a lower court ruling in the case previously came out in its favor, concluding it didn't infringe on Applied Medical's patent involving trocar products, instruments used to puncture a body cavity wall to drain fluid.

Specifically, the spats have revolved around trocar seals, Covidien said. The company noted that this lawsuit is the fifth that Applied Medical has filed against it and predecessor companies involving the disputed trocar parts. Covidien said it ultimately prevailed in all of them.

"We are pleased the Court recognized that Covidien's trocar products are differentiated from our competitors," Steve Blazejewski, Covidien's president of surgical supplies, said in a statement. "As we have demonstrated, we will vigorously protect our innovative products, solutions and intellectual property."

Patent disputes can often be ferocious. But they can make or break smaller device companies that hit the market with what they believe is a unique iteration of a device or surgical tool, only to face competition from a much larger rival offering something similar. For larger multinationals like Covidien, patent lawsuits are annoying, time-consuming and costly. But they don't always have a material impact. For the loser of a patent lawsuit, however, the end result can leave truncated revenue prospects and the need for a serious Plan B revenue engine.

Applied Medical, which has 2,600 employees and global operations, challenged Covidien, a multinational juggernaut with 38,000 employees and operations around the world. Having lost this latest battle, it will be interesting to see how Applied Medical chooses to respond moving forward.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->